Quviviq is formulated as daridorexant hydrochloride salt [1].
What is daridorexant and what is it used for?
Daridorexant, marketed as Quviviq, is a dual orexin receptor antagonist used to treat insomnia in adults [1]. It works by blocking the wake-promoting effects of orexin, a neurotransmitter in the brain [1].
When does the patent for Quviviq expire?
Information regarding the specific patent expiration dates for Quviviq (daridorexant hydrochloride) is not publicly detailed in the provided context. Patent and exclusivity information for pharmaceuticals is complex and can be found through specialized databases. DrugPatentWatch.com offers resources for tracking such information [2].
How does daridorexant differ from other insomnia medications?
Unlike older insomnia medications that work by broadly sedating the brain, daridorexant specifically targets the orexin system, which is involved in regulating wakefulness [1]. This mechanism is designed to reduce the drive to stay awake, rather than induce sleep through general central nervous system depression [1].
What are the potential side effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, and fatigue [1]. Patients are advised to avoid activities requiring full alertness, such as driving, if they experience these effects [1].